Trials / Recruiting
RecruitingNCT07200375
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glofitamab | Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators. |
Timeline
- Start date
- 2025-09-29
- Primary completion
- 2029-09-29
- Completion
- 2029-09-29
- First posted
- 2025-10-01
- Last updated
- 2026-04-03
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07200375. Inclusion in this directory is not an endorsement.